Related Experiment Videos
Hematologic aspects of systemic mastocytosis.
1Department of Pediatrics, State University of New York, Stony Brook School of Medicine, USA.
Hematology/Oncology Clinics of North America
|July 26, 2000
Summary
Systemic mast cell disease (SMCD) often involves bone marrow and can cause low blood counts. Co-occurring severe blood disorders in SMCD patients typically lead to a poorer prognosis and more aggressive disease.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Systemic mast cell disease (SMCD) is defined by mast cell infiltration of the bone marrow.
- Peripheral blood cytopenias are common in SMCD.
- SMCD frequently coexists with other hematologic disorders, including myeloproliferative neoplasms, myelodysplastic syndromes, and lymphoreticular malignancies.
Purpose of the Study:
- To describe the clinical characteristics and outcomes of patients with systemic mast cell disease.
- To investigate the impact of coexisting hematologic disorders on the prognosis of SMCD.
Main Methods:
- Review of patient data including bone marrow biopsy, peripheral blood counts, and coexisting diagnoses.
- Clinical course and prognostic factors were analyzed.
Main Results:
- Bone marrow mast cell involvement and cytopenias are key features of SMCD.
- Coexistence with severe hematologic disorders is common and associated with a compressed clinical course and worse prognosis.
- Overt mast cell leukemia is a rare but recognized complication.
- Hemorrhage due to heparin release from mast cells can occur.
Conclusions:
- Systemic mast cell disease has significant hematologic manifestations.
- The presence of severe coexisting hematologic disorders portends a poor prognosis in SMCD patients.
- Careful monitoring for complications such as hemorrhage is essential.